Latest Breaking News On - Autifony therapeutics - Page 1 : comparemela.com

Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance

Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Rylaze enrylazeAndrean flynnEpidiolex epidyolexKristin bhavnaniBruce cozaddRedx pharmaCompany annual report on formAutifony therapeuticsCorporate developmentHead of global corporate communicationsJazz pharmaceuticalsGw pharmaceuticalsWerewolf therapeutics incOtsuka pharmaceutical co ltdAccess programSumitomo pharma co ltd

Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance

Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Redx pharmaKristin bhavnaniBruce cozaddRylaze enrylazeAndrean flynnEpidiolex epidyolexOtsuka pharmaceutical co ltdSumitomo pharma co ltdHead of global corporate communicationsCorporate developmentPrnewswire jazz pharmaceuticalsWerewolf therapeutics incAccess programHikma pharmaceuticalsCompany annual report on formSunosi to axsome therapeutics inc

Rx Rundown: Legend Biotech, CureVac, Roivant Sciences and more

Check out this week’s medical marketing news, people on the move and industry chatter.

United statesWilliam batesMyrcix bioHank conantWeber shandwickAlessandra nagyChris martinEdward benzRebecca zobbeMichael byrnesJean marie lehnBiopharma coregenCarole huntsmanMayukh sukhatmeLoubna bouarfaVianautis bio

Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders

Total Deal Value of Up to $770.5 million including Upfront Payment and Potential Milestone Payments Autifony Eligible to Receive Royalties on Future Net Sales .

United kingdomAutifony therapeutics limitedSv health investorsAutifony therapeutics ltdInternational biotechnology trustJazz pharmaceuticalsIp groupCharles largeChief executive officerAutifony therapeuticsPfizer ventures

Autifony Therapeutics Ltd: Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders

Autifony Therapeutics Ltd: Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomMelanie toyne sewell giulia lasagniIp groupAutifony therapeutics ltdJazz pharmaceuticalsAutifony therapeutics limitedInternational biotechnology trustSv health investorsTotal deal valueUpfront paymentPotential milestoneReceive royaltiesFuture netTherapeutics limitedCharles largeChief executive officer